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Abstract
Background: Cyclin B1, the regulatory subunit of cyclin-dependent kinase 1 (Cdk1), is essential
for the transition from G2 phase to mitosis. Cyclin B1 is very often found to be overexpressed in
primary breast and cervical cancer cells as well as in cancer cell lines. Its expression is correlated
with the malignancy of gynecological cancers.
Methods: In order to explore cyclin B1 as a potential target for gynecological cancer therapy, we
studied the effect of small interfering RNA (siRNA) on different gynecological cancer cell lines by
monitoring their proliferation rate, cell cycle profile, protein expression and activity, apoptosis
induction and colony formation. Tumor formation in vivo was examined using mouse xenograft
models.
Results: Downregulation of cyclin B1 inhibited proliferation of several breast and cervical cancer
cell lines including MCF-7, BT-474, SK-BR-3, MDA-MB-231 and HeLa. After combining cyclin B1
siRNA with taxol, we observed an increased apoptotic rate accompanied by an enhanced
antiproliferative effect in breast cancer cells. Furthermore, control HeLa cells were progressively
growing, whereas the tumor growth of HeLa cells pre-treated with cyclin B1 siRNA was strongly
inhibited in nude mice, indicating that cyclin B1 is indispensable for tumor growth in vivo.
Conclusion: Our data support the notion of cyclin B1 being essential for survival and proliferation
of gynecological cancer cells. Concordantly, knockdown of cyclin B1 inhibits proliferation in vitro as
well as in vivo. Moreover, targeting cyclin B1 sensitizes breast cancer cells to taxol, suggesting that
specific cyclin B1 targeting is an attractive strategy for the combination with conventionally used
agents in gynecological cancer therapy.
Published: 29 December 2008
BMC Cancer 2008, 8:391 doi:10.1186/1471-2407-8-391
Received: 15 April 2008
Accepted: 29 December 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/391
© 2008 Androic et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:391 http://www.biomedcentral.com/1471-2407/8/391
Page 2 of 11
(page number not for citation purposes)
Background
Breast and cervical cancers are the most frequent malig-
nancies in women worldwide [1,2]. Uncontrolled cell
proliferation, which is associated with the loss of the
proper cell cycle control, is a prominent feature in these
cancers. The cell cycle is controlled by a highly conserved
family of cyclin-dependent kinases (Cdks) and their regu-
latory subunits cyclins. Among the cyclins, cyclin B1 plays
a pivotal role as a regulatory subunit for Cdk1, which is
indispensable for the transition from G2 phase to mitosis.
Overexpression of cyclin B1 has been reported in various
human tumors, such as breast cancer, cervical cancer, gas-
tric cancer, colorectal cancer, head and neck squamous
cell carcinoma and non-small-cell lung cancer [3-9] and
its upregulation is closely associated with poor prognosis
in various types of cancers including breast cancer
[6,10,11]. Moreover, overexpression of cyclin B1 is
involved in the resistance to radiotherapy in head and
neck squamous cell carcinoma [8] and nuclear cyclin B1-
positive breast carcinomas are resistant to adjuvant ther-
apy [11]. More recently, it is reported that both antibodies
and T cells are generated in response to aberrant cyclin B1
expression in tumors like breast cancer [12,13], indicating
that overexpressed cyclin B1 could serve as one of the sig-
nals to initiate the communication between cancer cells
and their microenvironment.
The mechanisms accounting for overexpressed cyclin B1
are not yet totally understood. It has been reported that
the tumor suppressors p53 and BRCA1 negatively regulate
the promoter of cyclin B1 [14-17], whereas the oncogene
c-Myc positively regulates the expression of cyclin B1 in
cooperation with the loss of p53 [18]. The promoter of
cyclin B1 is also upregulated by 17beta-estradiol (E2),
insulin-like growth factor I (IGF-I) and prolactin-releasing
hormone (PRL), which are considered as the factors con-
tributing to mammary cancer development and progres-
sion [19-21]. Moreover, cyclin B1 mRNA is significantly
stabilized in cervical cancer cells infected with human
papillomavirus type 18 (HPV 18) through upregulating
HuR [22], a ubiquitously expressed member of the Hu
family of RNA-binding proteins.
The highly expressed cyclin B1, even in G1 phase, binds to
its partner Cdk1, which phosphorylates a series of sub-
strates regardless of the cell cycle phase and contributes to
the aggressive proliferation in neoplastic tissues [23]. In
addition, overexpression of cyclin B1 is related to aneu-
ploidy and high proliferation of human mammary carci-
nomas [24]. This is consistent with the observation of
cyclin B1 overexpression enabling cells to override the G2
DNA damage checkpoint [16,25,26]. Nuclear cyclin B1,
together with Cdk1AF, a Cdk1 mutant that cannot be
phosphorylated at its inhibitory sites, induced a striking
premature mitotic phenotype even after DNA damage
[25,26], resulting in accumulation of genomic defects,
one hallmark of neoplastic development. More strikingly,
enforced expression of cyclin B1 induces tetraploidy,
either after mitotic spindle inhibition of nocodazole or in
the absence of such inhibition if cyclin B1 is coexpressed
with c-Myc [18].
Taken together, deregulation of cyclin B1 is involved in
neoplastic transformation and promotes proliferation of
tumor cells. Conversely, downregulation of cyclin B1,
consequently reducing the activity of Cdk1/cyclin B1,
could block the aggressive proliferation of tumor cells.
Indeed, our previous data confirm that interfering with
cyclin B1 function inhibits proliferation of human tumor
cells [27,28]. In the present study, we focus on gynecolog-
ical cancer cell lines and investigate the effect of small
interfering RNA (siRNA) induced cyclin B1 knockdown
on tumor cell proliferation. Interestingly, the combina-
tion of cyclin B1 siRNA with taxol substantially enhanced
the inhibitory effect on proliferation of breast cancer cells.
Furthermore, while control HeLa cells were progressively
growing, the tumor growth of HeLa cells treated with cyc-
lin B1 siRNA prior to inoculation was strongly inhibited
in nude mice, indicating cyclin B1 is indispensable for
tumor growth in vivo.
Methods
Cell culture, reagents and cell synchronization
Cervical cancer cell line HeLa and breast cancer cell lines
MCF-7, BT-474, SK-BR-3 and MDA-MB-231 were
obtained from DSMZ (Braunschweig). Fetal calf serum
(FCS) was purchased from PAA laboratories (Cölbe).
Opti-MEM I, oligofectamine, glutamine, penicillin, strep-
tomycin and trypsin were obtained from Invitrogen (Karl-
sruhe). Taxol was from Mayne Pharma (Haar). Cells were
synchronized to G1/S boundary by a double-thymidine
block. Briefly, cells were treated with 2 mM thymidine
(Sigma-Aldrich, Taufkirchen) for 16 h, released into fresh
medium for 8 h and subjected again to thymidine for fur-
ther 16 h. To obtain prometaphase arrest, after initial thy-
midine incubation and 8 h release cells were exposed to
50 ng/ml nocodazole (Sigma-Aldrich) for 14 h.
Transfection of siRNA and the combined treatment with 
drugs or irradiation
Four siRNAs targeting cyclin B1 (NCBI accession number
of cyclin B1: NM 031966) were synthesized by Dhar-
macon Research, Inc. (Lafayette), referred to as siRNA1-4.
siRNA1 against cyclin B1 corresponds to positions 340–
360 of the cyclin B1 open reading frame, siRNA2 to posi-
tions 476–496, siRNA3 to positions 776–796 and siRNA4
to positions 1302–1322. Control siRNA targeting green
fluorescent protein (siGFP) was also purchased from
Dharmacon. All siRNAs were 21 nucleotides in length and
contained symmetric 3' overhangs of two deoxythymi-
dines.BMC Cancer 2008, 8:391 http://www.biomedcentral.com/1471-2407/8/391
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Cells were transfected with siRNA using transfection rea-
gent oligofectamine, according to the manufacturer's
instructions (Invitrogen). In brief, one day prior to trans-
fection, cells were seeded without antibiotics to a density
of 50–60%. In all experiments cells were transfected with
siRNA1-4 or siGFP at a concentration of 10 nM. Cells were
harvested 48 h after siRNA-treatment for cell cycle evalua-
tion, Western blot analysis and kinase assay. The time
kinetics of protein expression were carried out at 24 h, 48
h, 72 h and 96 h and proliferation assays were performed
at 24 h, 48 h and 72 h after siRNA transfection in MCF-7
cells.
For chemotherapeutic treatment, MCF-7 cells were at first
transfected with siRNA and 4 h later followed by treat-
ment of taxol (3 ng/ml). For irradiation, 6 h post transfec-
tion cells were exposed to a single dose of 8 Gy at room
temperature by a linear accelerator (SL 75/5, Elekta, Craw-
ley, UK) with 6 MEV photons/100 cm focus-surface dis-
tance and a dose rate of 4.0 Gy/min. 48 h after
transfection of siRNAs cells were harvested for prolifera-
tion assay, cell cycle analysis and apoptosis evaluation.
Western blot analysis and kinase assay in vitro
Cell lysis was performed in RIPA buffer (50 mM Tris-HCl
pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% Na-desoxycho-
late, 0.1% SDS, 1 mM Na3VO4, 1 mM phenylmethyl-
sulphonyl-fluoride (PMSF), 1 mM Dithiothreitol (DTT),
1 mM NaF, and protease inhibitor cocktail Complete
(Roche, Mannheim)). Total protein was separated by
using 12% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and then transferred to
Immobilon-P membranes (Millipore, Bedford, MA).
Membranes were exposed to corresponding antibodies
for 1 h in PBS containing 5% slim milk, washed with
phosphate-buffered saline (PBS) containing 0.2%
Tween-20, incubated subsequently with secondary anti-
bodies for 1 h. Finally, the protein bands were visualized
with the enhanced chemiluminescence reagent (ECL,
Pierce, Rockford). Mouse monoclonal antibodies against
cyclin B1 (1:5,000), Cdk1 (1:2,000), anti-mouse second-
ary antibodies (1:4,000) and anti-rabbit secondary anti-
bodies (1:4,000) were purchased from Santa Cruz
(Heidelberg). Rabbit polyclonal antibodies against
PARP (poly(ADP-ribose) polymerase, 1: 1000) were
from Cell Signaling Technology (Beverly). Mouse mono-
clonal antibodies against β-actin (1:200,000) were
obtained from Sigma-Aldrich. Western blots were quan-
tified by applying a Kodak gel documentation system
(model 1D 3.5) and standardized with loading control.
For kinase assays in vitro, antibodies against cyclin B1
(Santa Cruz, Heidelberg) were used for immunoprecipi-
tation from 600 μg of cellular extracts. 0.5 μg histone H1
(Calbiochem, Darmstadt) served as substrate for each
reaction. Kinase assays were performed as previously
described [29].
Cell proliferation, cell cycle analysis and apoptosis assay
Cell viability was assessed by trypan blue staining. The
proliferation rate of cells was determined at indicated
time points by counting cell numbers with a hemacytom-
eter. All experiments were performed in triplicate. For cell
cycle analysis, cells were harvested, washed with PBS and
fixed in 70% chilled ethanol at 4°C for 30 min, then
treated with 1 mg/ml of RNase A (Sigma-Aldrich) and
stained with 100 μg/ml of propidium iodide for 30 min.
The DNA content of 10,000 cells was determined with a
fluorescent-activated cell sorter FACScan (Becton Dickin-
son Biosciences, Heidelberg). The data were analysed with
cell cycle analysis software ModFit LT 2.0 (Verity Software
House, Topsham, ME). Most of the experiments were per-
formed in triplicate. Indirect immunofluorescence stain-
ing for subcellular cyclin B1 localization and DNA were
carried out as previously described [29]. Apoptosis was
assessed using Vybrant™ apoptosis assay kit according to
the manufacturer's instructions (Molecular Probes, Lei-
den).
Colony formation assay and in vivo experiments
MCF-7 cells were treated with siRNA1-3 or siGFP for 48 h
and harvested for colony formation assays. Briefly, cells
were seeded in 24 well-plates at a density of 200 cells/well
into culture medium containing 0.3% agar (Roth, Karl-
sruhe) overlaying 0.5% agar. Cells were cultured at 37°C
with 5% CO2, and colonies were counted 4 weeks later
using a microscope (Zeiss, Oberkochen). The colony
number in control sample was referred as 100% by quan-
tification.
As to experiments in vivo, HeLa cells were treated with
siRNA3 or siGFP and harvested after 48 h. HeLa cells (1 ×
106) were resuspended in 300 μl of 0.9% NaCl and subcu-
taneously injected into both flanks of nude mice. Each
group contained 4 mice. Three weeks after inoculation the
tumor sizes were measured every 3–4 days using callipers
and the tumor volumes were calculated according to a
standard formula: π/6 × length × width2. The tumor vol-
umes within the group were represented by the mean
value. All mice were properly treated in accordance with
the guidelines of the local animal committee.
Statistic analysis
For assays in vitro, Student's t-tests were used to evaluate
the significance of difference between control cells and
siRNAs-treated cells. Differences were considered as statis-
tically significant when p < 0.05. With xenograft mouse
model, the significant difference between the siGFP-
treated group and siRNA3-treated group was analyzed by
Mann-Whitney U test.
Results
Cancer cell lines lend themselves as useful models to fur-
ther our understanding of gynecological cancers such asBMC Cancer 2008, 8:391 http://www.biomedcentral.com/1471-2407/8/391
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breast and cervical cancer. To study the function of cyclin
B1 in breast cancer cells we selected cancer cell lines MCF-
7, BT-474, SK-BR-3 and MDA-MB-231, as they represent
the best characterized cell lines for breast cancer research.
While MCF-7 and BT-474 express both estrogen receptor
(ER) and progesterone receptor (PgR), SK-BR-3 and MDA-
MB-231 cells lack those receptors [30]. Unlike SK-BR-3
and BT-474, which are Her-2/neu-positive, MCF-7 cells
only exhibit a basal level of Her-2/neu [30]. In addition,
MCF-7 cells express high amounts of markers typical of
the luminal epithelia phenotype of breast cells, whereas
BT-474 and SK-BR-3 cells exhibit a weakly luminal epithe-
lia-like phenotype. Distinct from the two phenotypes
above, MDA-MB-231 represents a highly invasive “mesen-
chymal-like“ breast cancer cell line by expressing a high
level of vimentin. In addition, the cervical cancer cell line
HeLa was selected, because it represents the most exten-
sively studied cancer cell line thus far.
Specific downregulation of cyclin B1 with siRNA
We were at first interested whether breast cancer cell lines
are similarly sensitive to specific downregulation of cyclin
B1 by siRNA. As shown in Fig. 1A, while the protein level
of cyclin B1 in MDA-MB-231 was almost undetectable
after treatment with siRNA1 or siRNA3, 33% and 16% of
cyclin B1 were still detectable in MCF-7 cells after treat-
ment with siRNA1 and siRNA3, respectively, relative to
the protein level of cyclin B1 in control cells. In contrast
to cyclin B1, β-actin was not affected. The protein level of
Cdk1, the catalytic partner of cyclin B1, hardly changed,
indicating cyclin B1 knockdown by siRNAs was specific.
Treatment of BT-474 and SK-BR-3 cells with siRNA1 and
siRNA3 also reduced cyclin B1 levels, albeit to a lower
extent as compared to MDA-MB-231 and MCF-7 cells.
Downregulation of cyclin B1 was also corroborated by
indirect immunofluorenscence staining with monoclonal
specific antibodies against cyclin B1 (data not shown).
Furthermore, in consistence with downregulation of cyc-
lin B1 protein, the kinase activity of Cdk1/cyclin B1 was
decreased to 28% in cellular extracts from siRNA1-treated
BT-474 cells as compared to siGFP-treated cells (Fig. 1B).
Similar results were also obtained in MCF-7 cells after
siRNA administration (data not shown).
Proliferation is inhibited in breast cancer cells with reduced 
cyclin B1
As Cdk1/cyclin B1 is essential for the initiation of mitosis
and required for cell division we subsequently studied the
impact of cyclin B1 downregulation on cell proliferation
rate. Expectedly, a reduced proliferation was observed in
all four breast cancer cell lines after 48 h treatment with
siRNAs as compared to control cells treated with siGFP
(Fig. 2). In particular, MCF-7 cells exhibited a strong inhi-
bition of proliferation, followed by MDA-MB-231, BT-
474 and SK-BR-3 cells after 48 h siRNA1-3 treatment
against cyclin B1 (Fig. 2A–D, upper panels). Analyses of
cell cycle distribution displayed an accumulation of cells
in G2/M phase, suggestive of a G2/M arrest, after treat-
ment with siRNA1-3 targeting cyclin B1 (Fig. 2A–D, lower
panels).
Time kinetics of siRNA treatment in MCF-7 cells
In order to study the effect of cycin B1 knockdown on pro-
liferation, we subjected MCF-7 cells to more detailed time
dependent analysis. MCF-7 cells were treated with siRNA1
or siRNA3 and harvested for Western blot analysis and
proliferation assay at the indicated time points. The reduc-
tion of cyclin B1 protein levels were evident 24 h after
siRNA1/3 treatment as compared to control cells (Fig.
3A). This effect increased dramatically with time and after
96 h cyclin B1 protein became undetectable. In line with
the reduction of cyclin B1, the proliferation rate of MCF-7
cells was clearly inhibited at 24 h with siRNA3 treatment
and the inhibition became more striking with longer
exposure to siRNA1 (Fig. 3B).
Suppression of cyclin B1 renders cells more susceptible to 
taxol
Taxol (Paclitaxel®), a taxane frequently used in multidrug
regiments for the therapy of several solid tumors, binds to
the β-subunit of tubulin, thereby impairing the dynamics
of microtubules by promoting their polymerization, lead-
ing to mitotic arrest and apoptosis [31]. In order to
explore cyclin B1 knockdown as a possible combination
with taxol, we transfected MCF-7 cells with siRNA3 and
followed by further incubation with taxol. Cells were har-
vested 48 h posttransfection. As depicted in Fig. 4A, cyclin
B1 protein level was strongly reduced after siRNA3 treat-
ment. Cyclin B1 level was also decreased after treatment
with taxol at a low dosage of 3 ng/ml, possibly due to the
induction of apoptosis, and almost disappeared when
cells were pre-treated with siRNA3 (Fig. 4A, upper panel).
Indeed, PARP (poly(ADP-ribose) polymerase) was
cleaved in cells treated with taxol and more strongly
cleaved when siRNA3 was used together with taxol (Fig.
4A, middle panel), indicating that the combined treat-
ment triggers more robust apoptotic response. In addi-
tion, proliferation was inhibited to a higher extent after
the combined treatment (Fig. 4B). The results were further
correlated with the cell cycle analysis: a G2/M population
was more prominent in MCF-7 cells after the combined
treatment, compared to cells exposed to siRNA3 alone
(Fig. 4C). The data indicate that the combined therapy
activates more strongly caspase-3 independent apoptotic
pathways in MCF-7 cells as the caspase-3 gene is deleted in
MCF-7 cells [32]. Similar results were also obtained in
MDA-MB-231 cells: while siRNA3 or taxol alone reduced
proliferation by 33% and 31%, respectively, relative to
siGFP treatment, the combination of siRNA3 with taxol
resulted in a 65% reduction of proliferation (data notBMC Cancer 2008, 8:391 http://www.biomedcentral.com/1471-2407/8/391
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shown). Thus, the combined action of cyclin B1 knock-
down together with taxol enhances antiproliferative and
proapoptotic responses in breast cancer cells. Further-
more, we investigated the combination of knockdown of
cyclin B1 with irradiation. Irradiation enhanced the G2/M
population and induced more apoptosis in cyclin B1
reduced MCF-7 cells, compared to control cells (data not
shown).
Impaired colony-forming ability and inhibited tumor 
growth
Anchorage independent cell growth is one of the hall-
marks of malignant tumor cells. Given the notion of cyc-
lin B1 deregulation being involved in neoplastic
transformation and associated with malignancy grade of
tumors, we wondered whether knockdown of cyclin B1
protein might translate into reduced colony-forming abil-
Reduced cyclin B1 protein and kinase activity of Cdk1/cyclin B1 Figure 1
Reduced cyclin B1 protein and kinase activity of Cdk1/cyclin B1. A. Upper panel: Breast cancer cells MCF-7, BT-474, 
SK-BR-3 and MDA-MB-231 cells were treated with cyclin B1 siRNA1, siRNA3, GFP siRNA (GFP) or without treatment (C) for 
48 h. Cells were harvested and cellular lysates were prepared for Western blot analyses with antibodies targeting cylin B1, 
Cdk1 and β-actin. The later served as loading control. Lower panel: Quantification of cyclin B1 levels from Western blots 
(upper panel), normalized to β-actin. B. Kinase assay of Cdk1/cyclin B1 in vitro. BT-474 cells were treated with cyclin B1 
siRNA1 or siGFP or without treatment (C). 24 h later cells were lysed and Cdk1/cyclin B1 complex was immunoprecipitated 
by using antibodies against cyclin B1 from cellular extracts. Normal IgG served as negative control. Kinase assays were carried 
out with the precipitates in the presence of histone H1 as substrate.
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ity in MCF-7 cells. As shown in Fig. 5A, the colony num-
bers of MCF-7 cells treated with siRNA1-3 were strongly
reduced, in particular, in MCF-7 cells treated with siRNA3,
compared to controls.
Cervical carcinoma HeLa cells express a high level of cyc-
lin B1 (data not shown). In cell culture, only 25–30%
HeLa cells were left after 48 h treatment with siRNA3 tar-
geting cyclin B1 (data not shown). To further address
whether cyclin B1 is required for aggressive growth of
tumors in vivo, a xenograft experiment with HeLa cells was
performed in nude mice. Mice were inoculated with HeLa
cells treated 48 h with siRNA3 targeting cyclin B1 or
siGFP. As shown in Fig. 5B, tumor growth of HeLa cells
treated with siRNA3 prior to inoculation was effectually
retarded, in comparison with the growth of control HeLa
tumors. The data suggest that cyclin B1 is indeed required
in vivo for promoting proliferation of tumor cells and the
reduction of cyclin B1 slows down the tumor growth.
Inhibited proliferation after downregulation of cyclin B1 Figure 2
Inhibited proliferation after downregulation of cyclin B1. MCF-7 (A), BT-474 (B), SK-BR-3 (C) and MDA-MB-231 cells 
(D) were treated with siRNA1-3, or siGFP or oligofectamine alone (OF). After 48 h cells were harvested for cell number 
counting (upper panels in Fig. 3 A-D) and for cell cycle analysis (lower panels in Fig. 3 A-D). Cells without any treatment (C) 
served as control. The results of cell numbers are expressed as mean ± SD (n = 3) and statistically analysed. *P < 0.05, **P < 
0.01.
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Discussion
The prognosis of breast and cervical cancer patients has
been improved during recent years, related partly to
sophisticated surgery, radiotherapy and adjuvant systemic
therapy. Despite these advances, these cancers remain
major clinical problems by causing considerable morbid-
ity and mortality in women worldwide. Apart from the
standard approaches, novel potent molecular agents for
anticancer therapy are in great demand.
In this communication we show that the knockdown of
cyclin B1, the regulatory subunit of Cdk1, inhibited cell
proliferation and induced apoptosis in various breast and
cervical cancer cell lines. Importantly, siRNA mediated
cyclin B1 knockdown in combination with chemothera-
peutical agent taxol, enhanced the antiproliferative effect
on breast cancer cells. Interestingly, the reduction of cyclin
B1 in MCF-7 cells impaired colony-forming ability, a hall-
mark of malignancy in tumor cells. Moreover, while con-
trol HeLa cells were progressively growing, the tumor
growth of HeLa cells treated with siRNA targeting cyclin
B1 prior to inoculation was strongly inhibited in nude
mice, indicating cyclin B1 is indispensable for tumor
growth in vivo. Taken together, the data strengthen the
notion of cyclin B1 being required for the survival and
proliferation of breast and cervical cancer cells and deple-
tion/downregulation of cyclin B1 inhibits proliferation of
cancer cells in vitro as well as in vivo.
Recent genetic evidence demonstrates that Cdk1 is the
only Cdk sufficient to drive the mammalian cell cycle
because embryos from Cdk1-/- mice fail to develop to the
morula and blastocyst stages, whereas mouse embryos
lacking all interphase Cdks (Cdk2, Cdk3, Cdk4 and Cdk6)
undergo organogenesis and develop to midgestation [33].
These data underscore that Cdk1 is essential for cell cycle
regulation and a major force driving cell proliferation.
Cyclin B1, the regulatory subunit of Cdk1, controls the
activity of Cdk1 as it associates with and thereby activates
Cdk1, regulates its nuclear translocation and passively
mediates its inactivation when cyclin B1 is degraded at
anaphase transition. Cyclin B1 is fundamental for cell
proliferation. Uncontrolled expression of cyclin B1 is
associated with neoplastic transformation and gynecolog-
ical cancer development [5,9,11,34,35]. Overexpression
of cyclin B1 is believed to confer therapy resistance [8,11].
Time kinetics in MCF-7 cells Figure 3
Time kinetics in MCF-7 cells. MCF-7 cells were treated with cyclin B1 siRNA1, siRNA3, siGFP or without treatment (C). 
Treated cells were harvested at different time points as indicated for Western blot analyses with antibodies against cyclin B1, 
Cdk1 and β-actin (A) and for cell number determinations (B). The results of cell numbers are expressed as mean ± SD (n = 3).
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More sensitive to taxol in MCF-7 cells with reduced cyclin B1 Figure 4
More sensitive to taxol in MCF-7 cells with reduced cyclin B1. A. MCF-7 cells were transfected with siRNA3 or siGFP 
and 4 h later followed with treatment of taxol (C+, siGFP+ and siRNA3+) or without taxol (C, siGFP and siRNA3). 48 h after 
transfection cells were harvested for Western blot analyses with antibodies as indicated. β-actin served as loading control. 
PARP: poly (ADP-ribose) polymerase. B. Cells were treated as in A and cell numbers were counted. The results are expressed 
as mean ± SD (n = 3) and statistically analysed. *P < 0.05. C. MCF-7 cells were treated as in A and cell cycle was analyzed 
(upper panel) and distribution of cell cycle population was quantified (lower panel).
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Thus, targeting cyclin B1, leading consequently to the
inactivation of Cdk1, could be a promising specific strat-
egy for cell cycle intervention against breast and cervical
cancer.
In this work, as a proof-of-concept, the RNA interference
was used to downregulate/deplete cyclin B1 and a clear
antiproliferative effect was observed in all cancer cell lines
studied. Among the breast cancer cell lines investigated,
MCF-7 cells exhibited the strongest inhibitory effect on
cell proliferation after cyclin B1 siRNA treatment, fol-
lowed by MDA-MB-231, SK-BR-3 and BT-474 cells (Fig.
2), which possibly correlates with the cyclin B1 level in
exponential growing status of each cell line (data not
shown). Although the protein level of cyclin B1 in MDA-
MB-231 cells was nearly undetectable after siRNA1 or
siRNA3 transfection, the inhibitory impact was moderate
(Fig. 2D), suggesting the proliferation of MDA-MB-231
cells is not necessarily dependent on the normal level of
cyclin B1 and the little amount of remaining cyclin B1
might be sufficient for the survival of MDA-MB-231 cells.
Finally, SK-BR-3 and BT-474 cells were also not as sensi-
tive to siRNA treatment (Fig. 2B and 2C) as HeLa or MCF-
7 cells. This could be due to the cellular context of SK-BR-
3 and BT-474 cells, e.g. Her-2/neu+, which very often leads
to a hormone-independent proliferation of cells. Thus,
unlike in MCF-7 cells, targeting Her-2/neu or other factors
promoting G1/S transition could be more effective for
inhibiting cell cycle progression in SK-BR-3 and BT-474
cells, which has been shown by our previous study [36].
On that account, specific targeting of oncogene(s) in indi-
vidual cancer cell lines, like Her-2/neu in SK-BR-3 and BT-
474 cells, or cyclin B1 in MCF-7, could improve breast
cancer therapy. Collectively, downregulation/depletion of
cyclin B1 worked effectively in all gynecological cancer
cell lines tested. However, only in some cell lines, such as
MCF-7 and HeLa, cyclin B1 knockdown resulted in a
strong proliferative inhibition, most likely because prolif-
eration in those cell lines is more dependent on high cyc-
lin B1 levels as compared to other cell lines.
Taxane drugs represent the most important class of anti-
cancer agents and are integrated in multidrug-regiments
for the therapy of several solid tumors including gyneco-
logical cancers. Despite their relevant contribution in
ameliorating the quality of life and overall survival of can-
cer patients, drug resistance and site-effects hamper its
wide usage. Therefore, it is desirable to find new ways of
lowering drug dosage without losing effectiveness to limit
side-effects and possibly also to slow down drug resist-
ance. In this work, cyclin B1 siRNA in combination with
taxol, blocking entry into mitosis and targeting the transi-
tion of metaphase to anaphase, respectively, demon-
strated a high efficacy in inhibiting proliferation of MCF-
7 cells. The data suggest that specific targeting of cyclin B1
could sensitize some gynecological cancer cells, like MCF-
7 and MDA-MB-231 cells, to conventional chemothera-
peutic agents like taxol, thereby reducing their side-effects
by lowering their dosage.
Taken together, the data from this work further strengthen
the notion that cyclin B1 could be an attractive target for
potential anticancer therapy. Inhibiting cyclin B1 function
in combination with chemotherapeutic drugs could rein-
force the antiproliferative effect in a subset of cancers. As
RNA interference still faces the major challenge of system-
atic delivery [37], an alternative strategy could be small
molecule inhibitors targeting cyclin B, as its crystal struc-
ture is recently published [38]. In parallel to Cdk inhibi-
tors, which have been extensively under clinical
investigations, small molecule inhibitors against cyclin B1
Impaired colony-forming ability and reduced tumor growth Figure 5
Impaired colony-forming ability and reduced tumor 
growth. A. Colony formation assay. MCF-7 cells were 
treated with siRNA1-3 or siGFP. 48 h after transfection cells 
were transferred to soft-agar plates for further incubation. 4 
weeks later the colony numbers were scored with a micro-
scope. The colony number of control cells was regarded as 
100% for calculation. The data were expressed as mean ± SD 
(n = 3) and analysed by Student's t-test. *P < 0.05, **P < 0.01. 
B. Xenograft experiment in nude mice. 1 × 106 of HeLa cells 
treated with siRNA3 or control siGFP were subcutaneously 
injected into each flank of nude mice. Each group contained 4 
mice. Tumor sizes were measured every 2–3 days and tumor 
volumes were calculated. The data were statistically analysed 
by Mann-Whitney U test. *P < 0.05, **P < 0.01.
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could open up a new door for specific molecular cancer
therapy by interfering with its protein stability, binding
capacity to Cdk1 or its subcellular localization.
Conclusion
This work demonstrates that cyclin B1 is required for sur-
vival and proliferation of breast and cervical cancer cells.
Downregulation of cyclin B1 inhibits proliferation of
tumor cells in vitro as well as in vivo and sensitizes breast
cancer cells to taxol. The data indicate that the combina-
tion of reducing cyclin B1 with chemotherapeutic drugs
could be a new strategy for molecular intervention in a
subset of breast cancers.
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